Nanjing-based biotechnology start-up BioHeng Biotech today announced that it has raised a RMB100 million (US$14.8 million) series A financing round from Decheng Capital, an early-stage life science-focused venture capital firm.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access Over 11,000 stories and data posts over the past 8 years!Register Now
Already have an account or paid subscription?